NLRP3 and neoplasm: In an in vitro model employing OSCC cells and an in vivo xenograft model of oral cancer, an NLRP3 inflammasome inhibitor BAY-117082 significantly reduced NLRP3, ASC, caspase-1, IL-1β, and IL-18 expression and a reduction in tumor growth 50.